Clinical Trials on Progression of Multiple Myeloma or Plasma Cell Leukemia

Total 3665 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of California, San Francisco

Terminated

Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin Disease | Lymphoma, Mantle-Cell | Acute Lymphoblastic Leukemia | Lymphoma, T-Cell, Peripheral | Chronic Myelogenous Leukemia | Myelodysplasia | Lymphoma, Large-Cell, Diffuse | T-NK Cell Lymphoma

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Terminated

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Precancerous/Nonmalignant Condition | Secondary Myelofibrosis | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, San Francisco

Withdrawn

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Lymphoma | Leukemia | Plasma Cell Dyscrasia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Hairy Cell | Lymphoma, Mantle-cell

United States
Masonic Cancer Center, University of Minnesota

Completed

Allo HSCT Using RIC for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Non-Hodgkin's Lymphoma | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia and other conditions

United States
Notable Labs

Completed

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy ((ANSWer))

Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm

Spain, United States, Greece
University of Nebraska

Completed

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (Chemobrain)

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Mild Cognitive Impairment | Myelodysplastic Syndrome | Acute Lymphoid Leukemia | Effects of Chemotherapy | Non-hodgkin Lymphoma

United States
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Mayo Clinic

Recruiting

Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Plasma Cell Myeloma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma

United States, Puerto Rico
Sanofi

Terminated

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Plasma Cell Myeloma

Taiwan, United States, Czechia, France, Greece, Spain
Emory University
National Cancer Institute (NCI); Takeda; National Institutes of Health (NIH); Janssen...

Active, not recruiting

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

Plasma Cell Myeloma

United States
Jonsson Comprehensive Cancer Center
Amgen

Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant Condition

United States
Wake Forest University Health Sciences

Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Myelodysplastic Syndromes | Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Germ Cell Neoplasms | Immunodeficiency Diseases

United States
University of Nebraska
Astex Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Myelodysplastic Syndromes | Multiple Myeloma | Chronic Lymphocytic Leukemia | Peripheral T-cell Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
University of Alabama at Birmingham

Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin's Lymphoma | CLL / SLL | Waldenstroms

United States
University of California, San Francisco

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia

Follicular Lymphoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Aplastic Anemia | Myelodysplasia | NHL | Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (Bu Flu TBI)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Myelodysplastic/Myeloproliferative Neoplasms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Kiadis Pharma

Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Lymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic Leukemia

Canada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Malignant Neoplasm | Myeloproliferative Neoplasm | Indolent Non-Hodgkin Lymphoma | Acute Myeloid Leukemia in Remission | Refractory Anemia | Refractory Anemia With... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Hebei Senlang Biotechnology Inc., Ltd.
Cangzhou People's Hospital

Recruiting

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Lymphoma, B-Cell | Multiple Myeloma | Leukemia, T-Cell | Leukemia, B-cell

China
Mayo Clinic
University of Iowa

Completed

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Temple University

Completed

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Plasma Cell Myeloma

United States
Sanofi

Completed

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Plasma Cell Myeloma

France, Germany, Italy, Spain
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Plasma Cell Myeloma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
NYU Langone Health
National Cancer Institute (NCI)

Terminated

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Thrombocytopenia | Refractory Multiple Myeloma

United States

Clinical Trials on Progression of Multiple Myeloma or Plasma Cell Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations